Skip to content

Flatiron Health at ASCO 2023. Learn more.

Real-World Evidence

Endpoints: Real-world progression and its association with OS

August 11, 2019

Our summary

Flatiron’s follow-up study expands the previous pilot to evaluate real-world progression (rwP) abstraction at scale. This study confirmed relatively high completeness and agreement for the approach used in curating rwP events for an EHR dataset of over 30,000 patients with advanced non-small cell lung cancer.

Why this matters

Novel analytical approaches unlock new research avenues but need to be vetted in order to assess their validity. This study shows that Flatiron’s new approach to extract disease progression information from EHR-derived datasets is feasible, scalable and reliable, enabling analyses of associated endpoints (progression-free survival, time to progression) that yield clinically meaningful results.

Read the research

The research
Characterizing feasibility and performance of real-world tumor progression

 

Griffith SD, Miksad RA, Calkins G, You P, Lipitz NG, Bourla AB, Williams ER, George DJ, Schrag D, Khozin S, Capra WB, Taylor MD, Abernethy AP. Characterizing the feasibility and performance of real-world tumor progression end points and their association with overall survival in a large advanced non-small cell lung cancer dataset. JCO Clin Cancer Informatics. 2019. https://doi.org/10.1200/CCI.19.00013

Related Articles

Is the cancer better or worse? Our journey to curate tumor progression from the electronic health record

Generating real-world tumor burden endpoints from electronic health record data: Comparison of RECIST, radiology-anchored, and clinician-anchored approaches for abstracting real-world progression in non-small cell lung cancer

Real-world progression, treatment, and survival outcomes during rapid adoption of immunotherapy for advanced non–small cell lung cancer